Axitinib in1st Line Treatment for Patients With Advanced or Metastatic Papillary Renal Cell Carcinoma
Status:
Completed
Trial end date:
2019-07-01
Target enrollment:
Participant gender:
Summary
Multicenter, single arm, phase II study using a A'Hern single-stage procedure in patients
with locally advanced or metastatic papillary renal cell carcinoma (PRCC) in first-line
treatment.